{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T06:07:18Z","timestamp":1788847638056,"version":"build-2803163510"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the oncologic outcomes and safety profiles of Bacillus Calmette\u2013Gu\u00e9rin (BCG) versus gemcitabine\/docetaxel (Gem\/Doce) maintenance following BCG induction in treatment\u2010na\u00efve non\u2013muscle\u2010invasive bladder cancer (NMIBC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified patients with treatment\u2010naive NMIBC who received induction BCG followed by maintenance BCG per the Southwest Oncology Group Cancer Research Network protocol or Gem\/Doce monthly for 1\u2009year (2016\u20132026). Oncological outcomes included recurrence\u2010free survival (RFS), high\u2010grade RFS, progression\u2010free survival, and metastasis\u2010free survival. Adverse events were systematically assessed to evaluate treatment tolerability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 128 patients received BCG induction followed by either BCG maintenance (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200998; 76.6%) or Gem\/Doce maintenance (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200930; 23.4%). After a median follow\u2010up of 75.0 months (interquartile range [IQR] 66.7\u201386.5) in the BCG group and 22.5 months (IQR 14.8\u201342.9) in the Gem\/Doce group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), 3\u2010year RFS (80.0% vs. 83.8%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.8), 3\u2010year high\u2010grade RFS (83.4% vs. 92.2%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.7), 3\u2010year progression\u2010free survival (90.0% vs. 96.6%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.4), and 3\u2010year metastasis\u2010free survival (96.8% vs. 100.0%;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.3) were comparable between the BCG and Gem\/Doce maintenance groups, respectively. Multivariable Cox regression analysis confirmed that Gem\/Doce versus BCG maintenance was not associated with disease recurrence (hazard ratio 1.04; 95% confidence interval 0.39\u20132.83;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.9). Overall, Gem\/Doce maintenance was better tolerated, with fewer patients reporting adverse events (6.7% vs. 28%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.02) and no severe events observed during the maintenance phase. Limitations of the study include its retrospective design and the relatively small sample size of the Gem\/Doce cohort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Sequential Gem\/Doce maintenance following BCG induction achieved oncologic outcomes comparable to those with BCG maintenance, with improved tolerability, highlighting its feasibility as an alternative in cases of BCG intolerance or shortage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.70375","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T07:44:18Z","timestamp":1783151058000},"page":"640-649","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of maintenance BCG versus gemcitabine\/docetaxel following BCG induction in NMIBC"],"prefix":"10.1111","volume":"138","author":[{"given":"Pierre\u2010Etienne","family":"Gabriel","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Hospital  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Zhu","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Hospital  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Karim","sequence":"additional","affiliation":[{"name":"Rutgers New Jersey Medical School  Newark NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6879-6058","authenticated-orcid":false,"given":"Ahmed","family":"Eraky","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Hospital  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghav","family":"Gupta","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Hospital  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuben","family":"Ben\u2010David","sequence":"additional","affiliation":[{"name":"Tel Aviv Sourasky Medical Center  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Mehrazin","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Hospital  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wiklund","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Hospital  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Sfakianos","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Hospital  New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.06.045"},{"key":"e_1_2_10_3_1","article-title":"European Association of Urology guidelines on non\u2010muscle\u2010invasive bladder cancer (TaT1 and carcinoma in situ)\u2010a summary of the 2024 guidelines update","volume":"25","author":"Gontero P","year":"2024","journal-title":"Eur Urol"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003846"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67707-5"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.04.066"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.10.039"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2018.06.018"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2023.02.044"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.11.031"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2025.03.024"},{"key":"e_1_2_10_12_1","article-title":"Cost\u2010effectiveness analysis of treatments for bacillus Calmette\u2010Gu\u00e9rin\u2010unresponsive carcinoma in situ of the bladder","volume":"45","author":"Myers AA","year":"2025","journal-title":"Eur Urol"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2024.09.006"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2024.12.131"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-025-05613-5"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.0849"},{"key":"e_1_2_10_17_1","article-title":"Quality of life and cost\u2010effectiveness of intravesical gemcitabine\/docetaxel vs BCG in BCG\u2010na\u00efve non\u2010muscle\u2010invasive bladder cancer","volume":"4","author":"Srivastava A","year":"2025","journal-title":"BJU Int"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2026.111078"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.03.007"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000001065"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000524098"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.06.011"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2024.05.006"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003977"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2024.06.020"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/life14070789"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16827"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2024.10.012"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.70149"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16486"},{"key":"e_1_2_10_31_1","first-page":"85","article-title":"Multicenter experience with first\u2010line intravesical gemcitabine\u2010docetaxel versus bacillus Calmette\u2010Guerin for high\u2010risk non\u2010muscle invasive bladder cancer","volume":"43","author":"Yankelevich GR","year":"2025","journal-title":"J Urol (Abstract)"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.06.003"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70375","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bju.70375","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70375","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:28:16Z","timestamp":1788845296000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.70375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/bju.70375"],"URL":"https:\/\/doi.org\/10.1111\/bju.70375","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"2026-07-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}